Cancer Today Editors’ Picks: 2024
Our favorite Cancer Today stories from 2024, as picked by the editors.
Progress Against Cancer
Our favorite Cancer Today stories from 2024, as picked by the editors.
The Cancer Today editors share the most impactful reporting on cancer research from 2024.
Chest radiation may not be necessary for people with intermediate-risk breast cancer.
Active surveillance of DCIS patients may be an alternative to treatment, and guidelines add self-test for HPV.
The FDA approved cosibelimab-ipdl for certain skin cancers that cannot be treated with surgery or radiation. The U.S. Food and Drug Administration (FDA) has approved cosibelimab-ipdl (Unloxcyt) for the treatment of adult patients with...
Research finds certain people with low-risk DCIS may be able to forgo surgery or radiation.
HPV vaccine credited for decrease in cervical cancer deaths among young women, and new technology extends survival in locally advanced pancreatic cancer.
The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for the treatment of adult...
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now